Peptide quality testing: HPLC, mass spectrometry and COAs
A useful quality assessment separates identity, purity and amount. HPLC separates sample components under a specified method; mass spectrometry measures mass-to-charge signals that can support identity. Neither test, by itself, establishes every quality or safety property of a vial.
A useful COA review asks a separate question for each reported measurement. The analytical method must be fit for its intended purpose; the name of an instrument is not enough. Agree on the research specification before comparing suppliers.
Read HPLC, identity and content as different measurements
| Reported evidence | Question it can address | What must not be inferred |
|---|---|---|
| HPLC/UPLC peak-area percentage | Relative detected components under the stated separation and detection method | The vial’s net peptide mass or absence of every impurity |
| Mass spectrometry | Whether measured mass-to-charge signals support the proposed identity | Every structural feature or the total amount in the vial |
| A quantitative content assay | How much of the specified analyte was measured, with a justified method and units | Sterility, clinical effectiveness or a result for another lot |
| Sterility or endotoxin testing | Only the property evaluated by that separate test and sampling plan | A property omitted from the report or suitability for human use |
Batch-documentation checklist
- Record full compound identity, chemical form and blend composition.
- Match vial label, sample identifier, lot and report reference; do not substitute one for another.
- Verify the original record with the issuing laboratory; keep its URL and verification result.
- List each method, numerical result, units and required acceptance criterion; mark missing tests as not reported.
- Ask how the submitted sample is linked to the supplied lot; document discrepancies before accepting material.
Common questions
Does 99% HPLC purity prove the amount on the vial label?
No. As a hypothetical example, a label stating 10 mg and a report stating 99% chromatographic purity do not establish that 10 mg of peptide was measured. Look for a separate, applicable quantitative result. This is an explanation, not a result for any Locked Aminos lot.
Does an authentic COA prove every shipped vial was tested?
No. It authenticates a record for the identified submitted sample. Connecting that sample to the received material requires traceability, a relevant sampling plan and any incoming testing the study requires.
Put the method checklist to work on an actual report
Use the original COA walkthrough below for three issuer-hosted reports, separate blend-component results and an annotated reading companion. It explains why an HPLC-DAD identity statement must not be silently turned into mass-spectrometry confirmation and why a conformance badge cannot resolve an unclear appearance row.

What a purity percentage actually describes
A chromatographic percentage depends on the separation, detection method, integration and sample preparation. Ask which result is reported and how it was calculated. A prominent peak is not a universal inventory of all possible contaminants. Do not interpret 99% chromatographic purity as 99% measured peptide content, sterility or suitability for administration.
Identity and mass need context
Compare the expected chemical form with the report. A molecular mass signal can be consistent with a compound while leaving other questions unresolved. Sequence-specific analysis, reference standards and method validation may be needed for a particular research specification. Ask the laboratory what its method can and cannot distinguish.
A worksheet for the actual batch
Record the compound, chemical form, vial amount, lot, sample identifier, issuing laboratory, report reference and date. Then list each test with its method, result, units and acceptance criterion. Mark absent tests as not reported. Preserve the original report link and resolve inconsistencies before deciding whether the material meets the study specification.
Origin and pharmaceutical-grade claims are separate
A US shipping address does not establish where synthesis or filling occurred. Ask for records identifying the production stages, facilities and batch. Likewise, a purity result is not GMP certification or a marketing authorization. Terms such as pharmaceutical grade should be supported by the exact applicable specification and documentation, not inferred from an attractive label.
Sources and review scope
- FDA / ICH Q2(R2): analytical procedure validation
- FDA: peptide impurities and characterization concerns
Sources explain terminology and evidence limits. They are not commercial endorsements or approvals of catalog products. Check the original source for updates.
